Gastroenterologia Perugia – Coord. Prof. Stefano Fiorucci

- 02 SET 24
- 0
Prof. Stefano Fiorucci- Progetti PNRR 2024 -Nanocarriers development for treating fibrotic disorders
Nanocarriers for fibrotic disorders-Università degli Studi di Perugia-Prof. Stefano Fiorucci FIORUCCI PNRR progetti nazionali
- Posted in
- News
- Posted by
- Stefano Fiorucci
- 16 MAR 24
- 0
Just published: Bile acids function as LIFR antagonists
From Gastroenterology and Surgery from Department of Medicine and Surgery at the University of Perugia (Italy) and Department of Pharmacy at the University of Naples “Federico II”, Italy and University of Salerno (Italy)
- Posted in
- News
- Posted by
- Stefano Fiorucci

- 09 MAR 24
- 0
Matter in progress: Bile acids as leukemia inhibitory factor receptor (LIFR) antagonists
Bile acids are LIFR antagonists
- Posted in
- News
- Posted by
- Stefano Fiorucci
- 08 MAR 24
- 0
Recently Published Hepatology 2023 Jul 1;78(1):26-44
Hepatology 2023 Jul 1;78(1):26-44. doi: 10.1002/hep.32787. Epub 2022 Oct 12. Combinatorial targeting of G-protein-coupled bile acid receptor 1 and cysteinyl leukotriene receptor 1 reveals a mechanistic role for bile acids and leukotrienes in drug-induced liver injury Michele Biagioli 1, Silvia Marchianò 1, Cristina di Giorgio 1, Rosalinda Roselli 2, Martina Bordoni 1, Rachele Bellini 1,
- Posted in
- Blog,
- News
- Posted by
- Stefano Fiorucci

- 06 MAR 24
- 0
FXR and GPBAR1 signaling in the vascular system and liver in MASLD. A recent study published by JAHA 2023 highlights a role of bile acids in liver steatohepatitis and atherosclerosis
Vascular injury linked to metabolic dysfunction-associated steatotic liver disease (MASLD) By Stefano Fiorucci, MD and others Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G‐Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease Silvia Marchianò, Michele Biagioli, Martina Bordoni, Elva Morretta, Cristina Di
- Posted in
- Blog
- Posted by
- Stefano Fiorucci
- 06 MAR 24
- 0
Recently published- Bile acids and COVID19. From a gastroenterology and hepatology perspective. Biochem Pharmacology December 2023
A review article by prof. Stefano Fiorucci and its group on bile acids and COVID19. Pathogenetic and therapeutic implications. Bile acids and COVID19
- Posted in
- Blog
- Posted by
- Stefano Fiorucci
- 19 MAR 22
- 0
Just accepted for publication- Fiorucci S., et al- Novel dual CystLTR1 antagonist/GPBAR1 agonist effectively reverses liver steatosis- Frontiers in Pharmacology 2022
Precision Biotherapeutics SrL a Spinoff of the University of Perugia reports new preclinical data on its lead compound CHIN117 on liver steatosis CysLTR1-GPBAR1 agonist
- Posted in
- Blog
- Posted by
- Stefano Fiorucci
- 08 NOV 21
- 0
Prof. Stefano Fiorucci has been appointed as Associate Editor to IMMUNO, a new journal from MDPI
Flyer IMMUNO 2021
- Posted in
- Blog
- Posted by
- Stefano Fiorucci

Prof. Stefano Fiorucci

Laboratori

Contatti

News

Blog

Prof. Stefano Fiorucci- Progetti PNRR 2024 -Nanocarriers development for treating fibrotic disorders

Just published: Bile acids function as LIFR antagonists

Matter in progress: Bile acids as leukemia inhibitory factor receptor (LIFR) antagonists

Recently Published Hepatology 2023 Jul 1;78(1):26-44

FXR and GPBAR1 signaling in the vascular system and liver in MASLD. A recent study published by JAHA 2023 highlights a role of bile acids in liver steatohepatitis and atherosclerosis

Recently published- Bile acids and COVID19. From a gastroenterology and hepatology perspective. Biochem Pharmacology December 2023

Just accepted for publication- Fiorucci S., et al- Novel dual CystLTR1 antagonist/GPBAR1 agonist effectively reverses liver steatosis- Frontiers in Pharmacology 2022

Prof. Stefano Fiorucci has been appointed as Associate Editor to IMMUNO, a new journal from MDPI

Contatti

Post Recenti